AUTHORS
Hu Zhou, MD, Xuewen Song, PhD2, Mengjuan Li3, Bingjie Ding4, Yirong Zhao5, Baojie Ma6, Yan Yang7, Xi Tan8, Shuanghui Wei9, Lihui Qian10, Yuli Xie11, Jianjun Zou12
AFFILIATIONS
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
5 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
6 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
7 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
8 Shanghai Junshi Biosciences Co., Ltd, Shanghai, --- Select One ---, China
9 Shanghai Junshi Biosciences Co., Ltd, Shanghai, --- Select One ---, China
10 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
11 Suzhou Junjing Biomedical Technology Co.Ltd, Suzhou, China
12 Shanghai Junshi Biosciences Co., Ltd, Shanghai, --- Select One ---, China
ABSTRACT
Introduction
Nearly all patients with myelofibrosis (MF) eventually develop resistance or intolerance to JAK inhibitors (JAKi). XPO1 is a key protein responsible for the export of tumor suppressors and inflammatory regulators from the nucleus to the cytoplasm in MF. WJ01024, an oral XPO1 inhibitor, offers a distinct approach for the treatment of MF patients. Here we report the data from phase IA of this investigator-initiated study of WJ01024 as monotherapy or in combination with ruxolitinib in MF.
Methods
Phase IA consisted of dose escalation and dose expansion. Patients with MF who were relapsed, refractory, or intolerant to JAKi were assigned to receive WJ01024 monotherapy (rapid titration and a 3+3 design: 20, 40, 60, and 80 mg, orally, once weekly [QW]) in 4-week cycles or WJ01024 60 and 80mg (QW) plus concomitant ruxolitinib ≥ 5mg twice daily for dose escalation. 60 mg WJ01024 was selected for the dose expansion phase. Key endpoints were safety, PK profiles and preliminary efficacy (e.g., spleen volume reduction of ≥ 35% [SVR35], SVR25%, and ≥ 50% reduction in total symptom score [TSS50]).
Results
As of May 07, 2026, 20 patients (median age: 63.0 years; male: 55.0%; 16 primary MF, 2 post-essential thrombocythermia MF, 2 post-polycythemia vera MF) were enrolled, including 1, 2, 9 and 3 patients receiving WJ01024 20, 40, 60 and 80 mg, and 3 and 2 patients receiving 60 and 80 mg WJ10124 plus ruxolitinib, respectively. Thirteen patients had relapsed/refractory disease and 7 were intolerant to JAKi. At baseline, the median spleen volume was 1431.07 (range: 833.53-3046.11) cm3 and the median TSS was 16.5 (range: 2-32). No dose limiting toxicities, Grade ≥ 3 WJ01024-related gastrointestinal toxicities, and treatment-related adverse events (TRAEs) leading to treatment discontinuation occurred. All patients experienced treatment-related adverse events (TRAEs). The most common TRAEs were nausea (85.0%), weight decreased (65.0%), anemia (65.0%), vomiting (60.0%), decreased appetite (60.0%), and platelet count decreased (50.0%). Among the enrolled 20 patients, 6 achieved SVR35 and 9 achieved SVR25 at any time, and the SVR35 and SVR25 were 20% (4/20) and 25% (5/20) at week 24, respectively. Eight patients achieved TSS50, and the TSS50 at week 24 was 10% (2/20). Mean (standard deviation) absolute change in TSS from baseline was -4.4 (6.7). All the 3 patients receieving WJ01024 60 mg plus ruxolitinib achieved SVR35 and TSS50 at any time, with 66.7% and 33.3% patients achieving SVR35 and TSS50 at week 24. Dose-proportional increases in exposure (Cmax and AUC0?????) were observed for WJ01024 monotherapy from 20 to 80 mg. No drug-drug interactions are observed between WJ01024 and ruxolitinib.
Conclusions
Oral WJ01024 administered with or without ruxolitinib were tolerant in MF patients who were relapsed, refractory, or intolerant to JAKi, and showed encouraging antitumor activity.
DISCLOSURES
Hu Zhou, MD: Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China - Research Funding